胸部肿瘤放疗后行立体定向放疗的疗效及毒性  

Efficacy and toxicity of stereotactic radiotherapy after thoracic tumor radiotherapy

作　　者：温宁笑[1] 余晓龙[1] 王妍[1] 吴晓玲[1] 袁红梅[1] Wen Ningxiao Yu Xiaolong Wang Yan Wu Xiaoling Yuan Hongmei(Department of Oncology , Hospital of Armed Police Force Jiangxi Corps, Nanchang , Jiangxi 330030,Chin)

机构地区：[1]武警江西总队医院肿瘤科,南昌330030

出　　处：《重庆医学》2017年第9期1196-1198,共3页Chongqing medicine

摘　　要：目的探讨胸部肿瘤既往放疗后应用立体定向放射治疗(SRT)再次治疗的疗效及安全性。方法选择2012年7月至2014年11月该院收治的38例既往胸部曾接受常规放射治疗后再接受SRT的患者,治疗靶区包括肺部局部原发灶、复发灶、肺转移瘤。结果既往放疗的中位剂量是48Gy(30~56Gy),再接受SRT的中位生物学等效剂量(α/β=10.0,BED10)是62Gy(39~72Gy)。中位随访时间12.30月;1、2年局部无进展生存率(LPFS)分别76.32%和63.16%;中位无复发时间(RFS)和总生存时间(OS)为13.20、21.00个月。2、3级肺毒性分别为15.79%、7.89%。其他2~4级不良反应包括胸痛15.79%、乏力18.42%、皮肤损害2.63%,无5级毒性损害。结论 SRT能安全、有效地应用于既往接受胸部放疗的患者。Objective To investigate the efficacy and safety of using stereotactic radiotherapy（SRT）technique for conducting re-therapy after thoracic tumor radiotherapy.Methods Thirty-eight patients with SRT after receiving thoracic conventional radiotherapy（RT）in our hospital from July 2012 to November 2014 were selected.The treatment target area included the lung local primary lesion,recurrent lesions and lung metastasis tumor.Results Median dose of previous RT was 48Gy（30-56Gy）.Median biologically equivalent effective dose（alpha/beta=10.0,BED10）of receiving SRT was 62Gy（39-72Gy）.Median follow up time was 12.30months;1-,2-year local progression-free survival（LPFS）was 76.32%and 63.16%respectively.Median recurrence-free（RFS）and overall survival（OS）were 13.20 months and 21.00 months respectively.Grade 2and 3pulmonary toxicity was15.79% and 7.89% respectively.Other grade 2-4toxicities adverse reactions included chest pain（15.79%）,fatigue（18.42%）and skin lesion（2.63%）.No grade 5toxic injury occurred.Conclusion SRT can be safely and effectively used in the patients previously receiving thoracic RT.

关 键 词：胸部肿瘤 放射外科手术 治疗结果 毒性作用 

分 类 号：R730.55[医药卫生—肿瘤]